Purpose: To our knowledge no medication has been shown to be effective for preventing recurrent calcium phosphate urinary stones. Potassium citrate may protect against calcium phosphate stones by enhancing urine citrate excretion and lowering urine calcium but it raises urine pH, which increases calcium phosphate saturation and may negate the beneficial effects. Citric acid can potentially raise urine citrate but not pH and, thus, it may be a useful countermeasure against calcium phosphate stones. We assessed whether these 2 agents could significantly alter urine composition and reduce calcium phosphate saturation. Materials and Methods: In a crossover metabolic study 13 recurrent calcium phosphate stone formers without hypercalciuria were evaluated at the end of 3, 1-week study phases during which they consumed a fixed metabolic diet and received assigned study medications, including citric acid 30 mEq twice daily, potassium citrate 20 mEq twice daily or matching placebo. We collected 24-hour urine specimens to perform urine chemistry studies and calculate calcium phosphate saturation indexes. Results: Urine parameters did not significantly differ between the citric acid and placebo phases. Potassium citrate significantly increased urine pH, potassium and citrate compared to citric acid and placebo (p <0.01) with a trend toward lower urine calcium (p ¼ 0.062). Brushite saturation was increased by potassium citrate when calculated by the relative supersaturation ratio but not by the saturation index. Conclusions: Citric acid at a dose of 60 mEq per day did not significantly alter urine composition in calcium phosphate stone formers. The long-term impact of potassium citrate on calcium phosphate stone recurrence needs to be studied further.
Key Words: urinary tract, urolithiasis, calcium phosphates, potassium citrate, citric acid CALCIUM phosphate urinary stones account for around 15% of all stones analyzed, although the incidence has markedly increased in recent years.
1e3 CaP and CaOx SFs share several common metabolic risk factors, including hypercalciuria, which has been identified in 60% to 70% of CaP SFs, and hypocitruria in 30% to 50%. 4, 5 However, a notable distinction between these 2 stone types is the significantly higher UpH in CaP SFs. 4, 5 UpH above 6.0 is essential for CaP crystallization due to greater availability of divalent phosphate ions to form poorly soluble complexes with calcium. 6 CaP SFs are usually treated with fluids and thiazides, and dietary protein and sodium restriction to reduce recurrent stones by lowering calciuria and CaP supersaturation. 7 However, many CaP SFs experience stone recurrence despite compliance with these measures. 4 K 3 Cit has been shown to prevent the recurrence of diverse stone types but it has not specifically been evaluated as therapy in CaP SFs. 8e13 The alkali load provided by K 3 Cit lowers calciuria, thus, reducing CaP supersaturation. 14 Physiochemically the provision of alkali by K 3 Cit promotes the formation of soluble calcium citrate complexes and further lowers urinary CaP supersaturation. 15 In addition, citrate exerts a direct inhibitory role on CaP crystal agglomeration. 16 However, the beneficial effects of K 3 Cit treatment may be negated by the concomitant rise in UpH, which potentially increases the CaP stone risk. 17 At the same time soluble calcium phosphate complexes other than brushite and hydroxyapatite could form in urine at a higher UpH, potentially negating the adverse impact of a higher UpH on CaP supersaturation and alleviating the safety concerns regarding alkali therapy in CaP SFs. 18, 19 Another potential pharmacological countermeasure for CaP stones is H 3 Cit, which has the potential to raise urine citrate but not pH. 20, 21 It is conceivable that the physiological renal response of ingesting a neutral substance such as H 3 Cit is the excretion of ammonium citrate in urine. The degree of citraturia may be modest in terms of the acid-base balance but sufficient to protect against stones. To our knowledge the potential role of H 3 Cit as a countermeasure to CaP stones has not been assessed previously.
In this study we examined whether H 3 Cit and K 3 Cit could decrease CaP saturation and the risk of recurrent nephrolithiasis in CaP SFs.
MATERIAL AND METHODS

Study Participants
The study was approved by the institutional review board at our institution and all participants provided informed consent. Patients were recruited from the Mineral Metabolism and Urology clinics at our institution, and screened with 24-hour urine and fasting blood studies prior to enrollment.
Inclusion Criteria. Participants were of either gender, any ethnicity and 21 years old or older. The diagnosis of CaP stones was based on the most recent available stone composition determined by x-ray crystallography with more than 70% of stone components composed of CaP.
Exclusion Criteria. Individuals were excluded from study if they had urinary calcium excretion 300 mg per day or greater in men and 250 mg per day or greater in women, a history of struvite and/or ammonium urate on stone analysis, recurrent urinary tract infections, pregnancy, conditions altering the acid-base balance such as chronic diarrhea, creatinine clearance less than 60 ml/minute/ 1.73 m 2 , treatment with angiotensin 2 receptor blockers, angiotensin converting enzyme inhibitors, diuretics, antacids, alkali or carbonic anhydrase inhibitors. CaP SFs with hypercalciuria were recruited in a separate study.
Study Protocol
In this double-blind, placebo controlled, crossover study each participant was evaluated during 3 phases in randomized order. The 3 phases were placebo, H 3 Cit and K 3 Cit. Each phase was 1 week in duration, during which participants received study medications with a 1-week washout between phases (supplementary figure, http:// jurology.com/).
During the first 4 days of each phase participants were instructed to adhere to a low sodium diet at home with a calcium content of approximately 800 mg per day. On the last 3 days of each phase participants were placed on a frozen metabolic diet prepared by the metabolic kitchen at the Clinical and Translational Research Center, which provided 55% of calories from carbohydrate, 30% from fat and 15% from protein. The inorganic solute composition of the diet consisted of 800 mg (20 mmoles) calcium, 100 mEq sodium, 800 mg phosphorus (26 mmoles), 50 mEq potassium and 2 L distilled water daily. During the final 2 study days (days 6 and 7) participants collected 2, 24-hr urine samples, including 1 under mineral oil to measure urine chemistry and acidbase parameters (bicarbonate and titratable acidity) and the second sample for urine chemistry and crystallization studies. Fasting blood was obtained at the end of the second urine collection.
As the study medications participants received 3 tablets with breakfast and dinner during each 1-week phase, including 3, 10 mEq tablets of H 3 Cit twice daily during the H 3 Cit phase (60 mEq H 3 Cit per day); 2, 10 mEq K 3 Cit tablets and 1 placebo tablet twice daily during the K 3 Cit phase (40 mEq K 3 Cit per day); and 3 tablets twice daily of matching placebo during the placebo phase. Study tablets were prepared at a compounding pharmacy. All tablets were similar in appearance and size.
Study End Points
Urine analytes were assessed by established and previously described methods. 5 Values of urine electrolytes assessed on days 6 and 7 were averaged for each phase and urine saturation was calculated from these parameters. The SI Br was determined by JESS, version 6.5, 22 and the RSR Br was calculated by EQUIL2. 23 These 2 programs estimate brushite saturation differently due to the inclusion in JESS of additional soluble CaP complexes that are not included in EQUIL2. In addition, the JESS program was modified to recalculate SI Br after omitting phosphocitrate (CaCitPO 4 4e ) and dicalcium-dihydrogen phosphate [Ca 2 H 2 (PO 4 ) 2 ] complexes, which are 2 soluble CaP complexes not recognized by EQUIL2. 19 Based on methods previously used to study brushite crystallization in whole urine we assessed CGBr, representing the growth of brushite crystals when a small quantity of brushite crystals is added to urine. 24, 25 Brushite is a precursor phase of hydroxyapatite, justifying its examination.
A fresh aliquot of whole urine was obtained at the end of the second 24-hour urine collection. Urine was centrifuged, supernatant was filtered with a 0.22 mm filter and 0.25 mg/ml brushite was added. Urine was then incubated at 37C for 3 hours under constant stirring with UpH checked hourly and maintained constant at voided UpH during the experiments. After 3 hours 2 ml suspension were filtered, and calcium and phosphate concentrations were analyzed in the filtrate. A decrement in [Ca] Â [P] after seeding with brushite signified crystal growth while an increment in [Ca] Â [P] represented crystal dissolution.
We also measured the overall activity of urinary promoters and inhibitors to brushite crystallization as the FP. The FP represents the limit of brushite metastability, which is the initiation of spontaneous precipitation. The FP was obtained by adding increasing amount of calcium as calcium chloride to a series of urine aliquots at constant pH equivalent to voided UpH for 2 hours. It was identified by the point at which visible brushite precipitation was elicited. The calculated saturation index using calcium and phosphorus at that point represented FP brushite. 25 The FPR was calculated as the ratio of the activity product at precipitation to the activity product of urine.
Statistical Analyses
All data are presented as the mean AE SD. To assess the effect of K 3 Cit and H 3 Cit on stone risk parameters we compared results among the 3 phases of study using repeat measures ANOVA. Pairwise comparisons between the phases were further done when ANOVA showed significant differences across phases. All tests were performed 2-sided with a 0.05 significance level using SASÒ for WindowsÒ, version 9.0.
RESULTS
Demographics
We reviewed the records of 286 patients with CaP stones for inclusion/exclusion criteria. Of these patients 41 met inclusion criteria and were contacted for study enrollment. A total of 13 subjects agreed to participate and were enrolled, including 2 men and 11 women with a mean age of 41 AE 15 years and a mean body mass index of 26.7 AE 6.4 kg/m 2 . Table 1 lists participant baseline characteristics. fig. 1, D) . H 3 Cit did not significantly alter citraturia, calciuria, pH or ammonium compared to placebo (table 2, and fig. 1, B to D) . There was no significant difference in urine volume, sodium, sulfate or any remaining measured urinary parameter between the 3 phases (table 2) .
24-Hour Urine Parameters and Saturation Indexes
Brushite saturation calculated by EQUIL2 as the RSR Br was significantly higher for K 3 Cit than for H 3 Cit (p <0.05) with no difference in the RSR Br between H 3 Cit and placebo ( fig. 2, A) . On the other hand, there was a trend toward lower brushite saturation for K 3 Cit when calculated in JESS as the SI Br . When the 2 calcium phosphate complexes calcium phosphocitrate and dicalcium-dihydrogen phosphate, were omitted from JESS the pattern of saturation became similar to that of the RSR Br ( fig. 2, A and B) . 
Crystallization Studies
There was no significant difference in the CG Br between the placebo, K 3 Cit and H 3 Cit phases 3 hours after adding a 0.25 mg/ml brushite seed ( fig. 3, A) . In experiments testing the formation product of brushite the concentration of calcium at the precipitation point was significantly lower for K 3 Cit than for placebo and H 3 Cit (p ¼ 0.035, fig. 3, B) . The brushite FPR did not significantly differ between the 3 phases ( fig. 3, C ) .
DISCUSSION
To our knowledge this is the first metabolic study to determine whether H 3 Cit or K 3 Cit could reduce CaP saturation and presumably the risk of recurrent CaP stones. Using a crossover design we compared the effects of H 3 Cit and K 3 Cit vs placebo on urinary stone risk factors in normocalciuric CaP SFs who consumed a controlled metabolic diet. We found that H 3 Cit did not significantly alter urinary citrate, other urinary parameters or brushite saturation and crystallization compared to placebo. On the other hand, K 3 Cit significantly increased citraturia and UpH, and marginally lowered calciuria. Urine saturation with respect to brushite was higher for K 3 Cit compared to H 3 Cit when estimated as the RSR Br by EQUIL2, although it tended to be lower when assessed as the SI Br by JESS. This discrepancy is largely explained by the inclusion in JESS of 2 soluble calcium phosphate complexes that are not included in EQUIL2. In crystallization experiments done in urine samples collected during the metabolic study no difference was found in the CG Br or the FPR Br .
In previous in vitro studies urinary citrate was found to form soluble complexes with urinary calcium, preventing CaP precipitation and potentially leading to a reduction in stone formation. 24 A randomized, placebo controlled trial showed that K 3 Cit reduced stone recurrence in CaOx and mixed CaOx/ CaP stone formers likely by the dual mechanisms of increasing citraturia and decreasing calciuria. 11 Furthermore, in prospective observational studies K 3 Cit significantly reduced stone recurrence in patients with incomplete distal renal tubular acidosis and medullary sponge kidneys, which are 2 conditions that frequently present with CaP stones. 9, 26 Despite these observations the role of citrate in preventing CaP stone recurrence had not been specifically studied.
In the current study K 3 Cit significantly increased UpH and citraturia, and decreased urinary ammonium as expected from an alkali load ( fig. 1) . However, it marginally lowered calciuria, in contrast to the marked urinary calcium reduction in patients with incomplete distal renal tubular acidosis who are given alkali. 9 Brushite saturation with K 3 Cit was higher when estimated as the RSR but it tended to be lower when assessed as the saturation index due to the inclusion of additional soluble CaP complexes in JESS ( fig. 2 ). Based on a previous in vitro study in which the SI Br approximated empirically measured brushite saturation better than RSR Br 19 it is plausible that K 3 Cit could reduce brushite saturation. In our crystallization studies at voided UpH K 3 Cit had no significant impact on the CG Br , although metastability studies showed precipitation at a lower calcium concentration and a trend toward a lower FPR Br for K 3 Cit than for H 3 Cit and placebo ( fig. 3) . In a recent report K 3 Cit increased citraturia and UpH, and lowered calciuria in genetic hypercalciuric stone forming rats, 27 similar to our findings. Furthermore, CaP supersaturation measured by EQUIL2 (the relative supersaturation ratio) was higher for K 3 Cit compared to the control. K 3 Cit treated and control animals had similar numbers of exclusively CaP stones, suggesting no beneficial effect in preventing CaP stone formation. To our knowledge the long-term impact of K 3 Cit on clinical CaP stone events and progression remains to be determined in humans.
Unlike K 3 Cit, which provides an alkali load and raises UpH, H 3 Cit does not alter the acid-base balance and should not modify UpH. Single dose H 3 Cit was previously found to modestly and transiently raise citraturia in healthy nonstone forming volunteers. 20 However, in the current study we found no significant impact of H 3 Cit vs placebo on 24-hour urine parameters or in crystallization studies. The discrepancy between the current results and the previously reported citraturic effect of H 3 Cit may be related to differences in the study population (CaP SFs vs nonstone formers), the followup duration and/or the dose (60 mEq/24 hours vs 40 mEq/4 hours). The lack of citraturia with H 3 Cit ingestion may have been due to the metabolism of orally ingested H 3 Cit in the liver prior to reaching the systemic circulation with no significant impact on citraturia.
A clinical correlate to our results is the differential impact of orange juice vs lemon juice and/or lemonade on urine citrate and pH. A previous study demonstrated that an alkali load is delivered by administering orange juice but not lemonade despite equivalent citrate content. 28 These prior results were attributed to the cation accompanying citrate in orange juice vs lemonade (potassium vs hydrogen, equivalent to the provision of K 3 Cit vs H 3 Cit), 28 a finding highlighted by our study results. Our study has several limitations. The number of patients was relatively small, in part due to the restrictive inclusion criteria. We did not study hypercalciuric CaP SFs who may have benefited from thiazides for stone prevention. Participants were kept on a metabolic diet, which may not reflect the environment in which the CaP stones formed. However, such a diet controls for dietary variations which could have impacted comparisons between phases. In addition, we measured saturation and crystallization indexes as surrogates for stone formation. However, it has been shown that calculated urinary saturation indexes are associated with stone formation and a reduction in saturation is associated with lower stone formation. 29 Finally, crystallization studies were performed in voided bladder urine, which may not represent the urinary environment in nephron sites at which crystal growth and aggregation develop.
CONCLUSIONS
Overall our findings suggest that in CaP SFs there is no significant difference between citric acid and placebo with respect to urine chemistry and physiochemistry relevant to CaP stone prevention. The overall impact of K 3 Cit on stone recurrence in CaP SFs must be studied further in view of its variable effects on urinary saturation and its lack of definite benefit in terms of crystallization parameters.
